CN105596437A - Pharmaceutical composition containing furosemide for treating hypertension and preparation method of pharmaceutical composition - Google Patents
Pharmaceutical composition containing furosemide for treating hypertension and preparation method of pharmaceutical composition Download PDFInfo
- Publication number
- CN105596437A CN105596437A CN201610175836.4A CN201610175836A CN105596437A CN 105596437 A CN105596437 A CN 105596437A CN 201610175836 A CN201610175836 A CN 201610175836A CN 105596437 A CN105596437 A CN 105596437A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- frusemide
- treatment
- add
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229960003883 furosemide Drugs 0.000 title claims abstract description 60
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 50
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 30
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 230000001631 hypertensive effect Effects 0.000 claims description 32
- 238000002347 injection Methods 0.000 claims description 28
- 239000007924 injection Substances 0.000 claims description 28
- 229920003266 Leaf® Polymers 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 241000522169 Lespedeza Species 0.000 claims description 21
- 241000219051 Fagopyrum Species 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 239000011149 active material Substances 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 238000007796 conventional method Methods 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 240000008620 Fagopyrum esculentum Species 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 235000009852 Cucurbita pepo Nutrition 0.000 abstract 1
- 241000219104 Cucurbitaceae Species 0.000 abstract 1
- 244000228957 Ferula foetida Species 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000002892 effect on hypertension Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 208000030961 allergic reaction Diseases 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000134109 Ferula sinkiangensis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000303847 Lagenaria vulgaris Species 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001353520 Lespedeza virgata Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- -1 gallate ester Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition containing furosemide for treating hypertension and a preparation method of the pharmaceutical composition. The pharmaceutical composition containing the furosemide for treating the hypertension is prepared from the following raw materials in parts by weight: 10-30 parts of furosemide, 2,000-4,000 parts of lespedesa virgata, 2,000-4,000 parts of buckwheat leaves, 2,000-4,000 parts of gourds and 2,000-4,000 parts of ferula asafetida. The traditional Chinese medicine is combined with the furosemide, so that the common adverse reaction of the furosemide can be avoided; and the treatment effect on hypertension is improved.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the hypertensive pharmaceutical composition of a kind for the treatment of that contains frusemideAnd preparation method thereof.
Background technology
Hypertension is Important cause of disease and the hazards of cardiovascular and cerebrovascular disease, and the whole world has the people of 20%-30% to suffer from high bloodPress. Hypertension can affect the 26S Proteasome Structure and Function of the heart, brain, kidney, can significantly increase the onset risk of palsy, heart failure, ESRD.The investigation of 95%, 2002 year that essential hypertension accounts for hypertension incidence be presented at more than 18 years old prevalence of China up to18.8%, number of patients reaches 1.6 hundred million. Therefore hypertensive prevention and treatment, becomes great that China and the whole world pays close attention to the mostPublic health problem.
Current hypertensive methods for the treatment of is except changing habits and customs, and topmost effective interference method is exactly that medicine is controlledMalignant boil, conventional antihypertensive drugs is divided into 5 classes at present, clinically alone the and drug combination two class schemes of main employing. But step-downMedicine still has a lot of ask bad reaction, resistance phenomenon and patients that for example Long-term taking medicine causes in clinical applicationBad compliance. There are some researches show that the patient who accepts medicine treatment only has 53% successfully to control blood pressure, make controlling of blood pressure≤140/90mmHg。
Frusemide is the hypertensive loop diuretics of clinical conventional treatment, and when thiazide is invalid, these product may be effective, especiallyWhen with renal insufficiency or while there is hypertensive crisis, this class medicine is particularly applicable. The common bad reaction of frusemide wasQuick reaction (comprise fash, interstitial nephritis, even heart arrest), incidence is up to 20%, and this bad reaction has limited furan plugRice is in clinical use.
Summary of the invention
In order to solve the large restriction of frusemide side effect end user group's technical problem, the invention provides a kind of frusemide withThe composition of Chinese medicine, by with the compatibility of Chinese medicine, alleviate the bad reaction of frusemide, thereby realize the object of attenuation synergistic.
The present invention realizes by following technical scheme:
The hypertensive pharmaceutical composition for the treatment of that contains frusemide, is made up of the bulk drug of following weight proportion: frusemide10-30 part, virgate lespedeza herb 2000-4000 part, buckwheat leaf 2000-4000 part, cucurbit 2000-4000 part, asafoetide 2000-4000 part.
The above-mentioned hypertensive pharmaceutical composition of the treatment that contains frusemide, its weight portion proportion optimization is: frusemide 15-25 parts, virgate lespedeza herb 2500-3500 part, buckwheat leaf 2500-3500 part, cucurbit 2500-3500 part, asafoetide 2500-3500 part.
The above-mentioned hypertensive pharmaceutical composition of the treatment that contains frusemide, its weight portion proportioning the best is: frusemide 20Part, 3000 parts of virgate lespedeza herbs, 3000 parts of buckwheat leafs, 3000 parts, cucurbit, 3000 parts of asafoetides.
In above composition of the present invention, the weight of each taste Chinese medicine is calculated with crude drug, if in grams, as makesPreparation, because varying in size of preparation can be made into 100-1000 agent. Described 100-1000 agent refers to the dosage form of UD,As tablet 100-1000 sheet, capsule 100-1000 grain, granule l00-1000g, oral liquid l00-l000ml, paste l00-L000g, pill 100-1000 ball etc.
More than composition is by weight as proportioning, can increase or reduce according to corresponding proportion, as on a large scale in the time producingProduction can be taking kg as unit, or taking t(ton) be unit; Preparation also can be taking g as unit on a small scale. Weight can increase orReduce, but the constant rate of raw medicinal herbs weight proportion between each composition.
Through science, screening obtains the ratio of above weight proportion, for especial patient, as severe or light disease, obesityOr the patient of slight of stature, can be corresponding the proportioning of amount of adjustment composition, increase or reduce being no more than 100%, drug effect is substantially constant.
Pharmaceutical composition of the present invention, can add separately or as required some medicines of injection volume acceptable auxiliaryMaterial, can adopt galenic pharmacy routine techniques to prepare this pharmaceutical preparation, as pharmaceutically active substance and the acceptable auxiliary material of medicine are mixedClose. In the time making pharmaceutical preparation, can make any pharmaceutically useful peroral dosage form, these formulations are selected from: granule, tablet, capsuleAgent, oral liquid, suck agent, pill, powder, preferably granule.
The preparation method of the above-mentioned hypertensive pharmaceutical composition for the treatment of that contains frusemide, comprises following steps:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add 6 ~ 8 times of water gagings of injection volume for the 1st time, decoct 1 ~ 2Hour, add for the second time 4 ~ 6 times of water gagings of injection volume, decoct 0.5 ~ 1.5 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 55 ~ 65 DEG C ,-0.04 ~-0.08Mpa condition to relative density and is 1.08 ~ 1.12 clearCream, adds ethanol to being 75% containing alcohol amount, places 12 hours, filters, and it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, spraysMist is dried to obtain dry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material separately or mix with the acceptable auxiliary material of medicine, makes according to galenic pharmacy conventional method.
In the preparation method of the above-mentioned hypertensive pharmaceutical composition for the treatment of that contains frusemide, in the step a of portion of institute the 1st timeAdd 7 times of water gagings of injection volume, decoct 1.5 hours, add for the second time 5 times of water gagings of injection volume, decoct 1 hour; Described step bMiddle thickening temperature is 60 DEG C, concentrated pressure is-0.06Mpa.
Preferably, state the preparation method of the hypertensive pharmaceutical composition for the treatment of that contains frusemide, detailed step is as follows:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add 7 times of water gagings of injection volume for the 1st time, decoct 1.5 littleTime, add for the second time 5 times of water gagings of injection volume, decoct 1 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 60 DEG C ,-0.06Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried drylyDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material separately or mix with the acceptable auxiliary material of medicine, makes according to galenic pharmacy conventional method.
The acceptable auxiliary material of described medicine is selected from: starch, dolomol, sweet mellow wine, sorbierite, sorbic acid or sylvite,Sodium pyrosulfite, sodium hydrogensulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitaminC, tie up main plain E, vitamin D, azone, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or itsThe aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, dextran, sweet ammoniaAcid, lactose, mannitol, silicon derivative, cellulose and derivative thereof, alginates, gelatin, polyvinylpyrrolidone, glycerine, thirdGlycol, ethanol, polysorbate60~80, department class~80, beeswax, lanolin, atoleine, hexadecanol, gallate ester, three ethanolAmine, basic amino acid, urea, allantoin, calcium carbonate, calcium bicarbonate, surfactant, polyethylene glycol, cyclodextrin, β~ring are stuck with pasteEssence, phospholipid material, kaolin, talcum powder, calcium stearate etc.
The present invention treats hypertensive pharmaceutical composition and is applicable to treat essential hypertension, can be separately or with other step-downsMedicine use in conjunction.
The present invention treats hypertensive pharmaceutical composition usage and dosage:
Oral: to start cumulative dosage from low dose. Conventionally initial dose be one time 1 bag, 2 times on the one; Take with meal.
The present invention treats hypertensive pharmaceutical composition and is cautious use of in 1. anuria or severe renal hypothyroid, because of this class medicineWeak effect, application can cause drug accumulation when heavy dose of, and toxicity increases; 2. severe cardiac pulmonary dysfunction; 3. hyperuricemia orThere is gout medical history person; 4. serious hepatic disorder person, water, electrolyte disturbance can bring out hepatic coma; 5. hypercalcinemia; 6. lowPotassium mass formed by blood stasis; 7. lupus erythematosus, can increase the weight of the state of an illness or stimulate activity; 8. pancreatitis; 9. Sympathectomy person (hypotensive effectStrengthen); 10. there is the baby of jaundice.
In pharmaceutical composition of the present invention,
Virgate lespedeza herb is legume lespedeza virgata Lespedezavirgata(Thunb.) DC.[HedysarumvirgatumThunb.] herb. Taste is sweet; Micro-hardship; Property is put down. Return spleen; Lung channel. The clear heat diuresis of function; Preventing malaria. Main heatstroke; Difficult urination; MalariaDisease; Flu; Hypertension.
Buckwheat leaf is polygonaceae plant buckwheat FagopyrumesculentumMoench[F.sagot-tatumGilib.; PolygoneumfagopyrumL.] leaf. Taste acid; Cold in nature. Function profit knowledge; Lower gas; Hemostasis; Step-down. Dominant eyeBlurred vision is stuck with paste; Tinnitus is hard of hearing; Belch; Purpura; Hypertension.
Cucurbit another name loud, high-pitched sound Bei Zhebu (hiding name), deriving from this product is cucurbitaceous plant cucurbit Lagenariasiceraria(Molina) dry seed of Standl.. Taste acid, puckery, warm in nature. Function antidiarrheal, draws and tells. For hot dysentery, tuberculosis, fash.
The smoked canal of asafoetide another name, Wei Quji, Kazakhstan former times mud, multicolored Wei, RESINA FERULAE are samphire asafoetide FerulaAssafoetidaL., Ferula sinkiangensis FerulasinkiangensisK.MShen, beg health asafoetide FerulaThe resin of the secretion such as fukanensisK.M.Shan. Taste is pungent; Flat; Nontoxic. Return liver; Spleen; Stomach warp. Functionalization disease disappears long-pending; Desinsection;Preventing malaria. Primary symptom lump in the abdomen lump in the abdomen; Malnutrition due to parasitic infestation; Dyspepsia; Fullness and oppression of chest and abdomen; Crymodynia; Malaria; Dysentery.
Beneficial effect of the present invention is: the present invention combines Chinese medicine and frusemide, to avoid the common of frusemideBad reaction, and improve to hypertensive result for the treatment of. Clinical test results shows: oral the present invention is containing frusemide compositionPatient, preliminary judgement is being better than simple application frusemide person controlling aspect blood pressure level. In addition, of the present invention containing furan plugRice pharmaceutical composition is improving aspect frusemide adverse drug reaction than significantly (P < 0.05) of simple application frusemide person effect.Illustrate that the frusemide pharmaceutical composition that contains of the present invention truly has curative effect aspect reducing blood pressure, and have advantages of that side effect is little.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understandsThe present invention, but therefore do not limit the present invention.
Embodiment 1
One is treated hypertensive pharmaceutical composition, is made up of the bulk drug of following weight portion proportioning:
Frusemide 20g, virgate lespedeza herb 3000g, buckwheat leaf 3000g, cucurbit 3000g, asafoetide 3000g.
The preparation method of the hypertensive pharmaceutical composition of this treatment:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add injection volume 7 water gagings the 1st time, decoct 1.5 littleTime, add for the second time 5 times of water gagings of injection volume, decoct 1 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 60 DEG C ,-0.06Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried drylyDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material adds injection volume xylitol, sweet mellow wine and β~cyclodextrin, the appropriate granulation agent of adhesive.
Prepare altogether 1000 bags, every bag heavy 5g.
Embodiment 2
One is treated hypertensive pharmaceutical composition, is made up of the bulk drug of following weight portion proportioning:
Frusemide 15g, virgate lespedeza herb 3500g, buckwheat leaf 2500g, cucurbit 3500g, asafoetide 2500g.
The preparation method of the hypertensive pharmaceutical composition of this treatment:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add injection volume 8 water gagings the 1st time, decoct 2 hours,Add for the second time 6 times of water gagings of injection volume, decoct 1.5 hours, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 55 DEG C ,-0.08Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried drylyDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material adds injection volume xylitol, sweet mellow wine and β~cyclodextrin,, the appropriate granulation agent of adhesive.
Prepare altogether 1000 bags, every bag heavy 5g.
Embodiment 3
One is treated hypertensive pharmaceutical composition, is made up of the bulk drug of following weight portion proportioning:
Frusemide 25g, virgate lespedeza herb 2500g, buckwheat leaf 3500g, cucurbit 2500g, asafoetide 3500g.
The preparation method of the hypertensive pharmaceutical composition of this treatment:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add injection volume 6 water gagings the 1st time, decoct 1 hour,Add for the second time 4 times of water gagings of injection volume, decoct 0.5 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 65 DEG C ,-0.04Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried drylyDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material adds injection volume xylitol, sweet mellow wine and β~cyclodextrin, the appropriate granulation agent of adhesive.
Prepare altogether 1000 bags, every bag heavy 5g.
Embodiment 4
One is treated hypertensive pharmaceutical composition, is made up of the bulk drug of following weight portion proportioning:
Frusemide 10g, virgate lespedeza herb 4000g, buckwheat leaf 4000g, cucurbit 4000g, asafoetide 4000g.
The preparation method of the hypertensive pharmaceutical composition of this treatment:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add injection volume 7 water gagings the 1st time, decoct 1.5 littleTime, add for the second time 5 times of water gagings of injection volume, decoct 1 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 60 DEG C ,-0.06Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried drylyDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material adds injection volume xylitol, sweet mellow wine and β~cyclodextrin, the appropriate granulation agent of adhesive.
Prepare altogether 1000 bags, every bag heavy 5g.
Embodiment 5
One is treated hypertensive pharmaceutical composition, is made up of the bulk drug of following weight portion proportioning:
Frusemide 30g, virgate lespedeza herb 2000g, buckwheat leaf 2000g, cucurbit 2000g, asafoetide 2000g.
The preparation method of the hypertensive pharmaceutical composition of this treatment:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add injection volume 7 water gagings the 1st time, decoct 1.5 littleTime, add for the second time 5 times of water gagings of injection volume, decoct 1 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 60 DEG C ,-0.06Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried drylyDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material adds injection volume xylitol, sweet mellow wine and β~cyclodextrin, the appropriate granulation agent of adhesive.
Prepare altogether 1000 bags, every bag heavy 5g.
The pharmaceutical composition that contains frusemide prepared by embodiment 1 has carried out clinical testing, and result is as follows:
1. data and method
1.1 research object
100 routine primary hypertension patients have been selected in this research, all meet WHO diagnostic criteria in 1999, and meet withLower condition: 1. make a definite diagnosis for the first time or make a definite diagnosis and be no more than that do not treat half a year and systolic pressure >=140mmHg, diastolic pressure >=90mmHg; 2.Without serious acute and chronic complication. Qualified 100 routine patients are divided into observation group and control group at random, every group of 50 examples. Two groupsPatient aspect sex, age, body mass index, the course of disease, blood pressure level etc. very physical data comparing difference not statistically significant (P >0.05), there is comparativity.
1.2 methods for the treatment of
1. control group: apply frusemide treatment on the basis of patient being carried out to the education of hypertension health knowledge, frusemide is each20mg, every day 2 times. 2. observation group: use in conjunction contains furan on the basis of patient being carried out to the education of hypertension health knowledgeThe pharmaceutical composition of plug rice, each 1 bag, every day 2 times. Two groups all taking 1 week as one treatment stage.
1.3 observation index
1. safety indexes: as routine blood test, stool routine examination, liver function, kidney function test, electrocardiogram etc.; 2. health giving quality index: controlBlood pressure level before and after treating, blood pressure normalization rate (systolic pressure≤120mmHg, diastolic pressure≤90mmHg). 3. allergic reaction generation feelingsCondition.
1.4 statistical method
Adopt SPSS17.0 to carry out the statistical analysis of data. Measurement data adopts t inspection (by mean ± standard deviationRepresent); Grouped data adopts χ2Inspection, using P≤0.05 as there being statistical significance, using P≤0.01 as havingHeight statistical significance.
2. result
2.1 clinical efficacy results
Treat the systolic pressure of first two groups and the horizontal comparing difference not statistically significant of diastolic pressure (P > 0.05); After treatment two groupsSystolic pressure and diastolic pressure level all obviously reduce before treatment, and difference has statistical significance (P < 0.05); The patient of observation group existsSystolic pressure and diastolic pressure improve degree aspect and are obviously better than control group, and difference has statistical significance (P < 0.05); Observation group controlsBlood pressure normalization rate 98.0%(49/50 after treating) apparently higher than the 56.0%(28/50 of control group), difference have statistical significance (P <0.05); In table 1.
Table 1 liang group patient clinical curative effect comparison
Group | Number of cases | Time | Systolic pressure (mmHg) | Diastolic pressure (mmHg) |
Observation group | 50 | Before treatment | 166.25±13.51 | 109.62±11.47 |
After treatment | 104.15±9.85*# | 71.36±4.39*# 5 --> | ||
Control group | 50 | Before treatment | 166.36±13.53 | 109.66±11.49 |
After treatment | 125.75±11.37* | 95.66±5.98* |
Note: * represents and front relatively P < 0.05 for the treatment of; # represent with treatment of control group after P < 0.05 relatively
2.2 security observed results
In this test, all experimenter carries out respectively safety indexes detection before and after treatment, and result is not found obviously extremely to changeBecome, illustrate that the pharmaceutical composition that contains frusemide of the present invention uses safety.
A situation arises in 2.3 allergic reactions
In this research, the allergic reaction incidence of observation group is starkly lower than control group, and difference has statistical significance (P < 0.05),In table 2.
A situation arises in a table 2 liang group allergic reaction
Group | Number of cases | Pityriasis | Multiple erythroderma | Interstitial nephritis | Heart arrest | Incidence |
Observation group | 50 | 0 | 0 | 0 | 0 | 0(0.0%) |
Control group | 50 | 5 | 5 | 1 | 0 | 11(22.0%) |
The present invention combines Chinese medicine and frusemide, to avoid the common allergic reaction of frusemide, and improves hypertensionResult for the treatment of. Clinical test results shows: oral the present invention is containing the patient of frusemide composition, and preliminary judgement is being controlled blood pressureHorizontal aspect is better than simple application frusemide person. In addition, the frusemide pharmaceutical composition that contains of the present invention is improving frusemide medicineThing allergic reaction aspect, than significantly (P < 0.05) of simple application frusemide person effect, illustrates of the present invention containing frusemide medicine groupCompound is safe and effective aspect reducing blood pressure, and has advantages of that side effect is little.
Claims (7)
1. the hypertensive pharmaceutical composition for the treatment of that contains frusemide, is made up of the bulk drug of following weight portion proportioning: furanPlug rice 10-30 part, virgate lespedeza herb 2000-4000 part, buckwheat leaf 2000-4000 part, cucurbit 2000-4000 part, asafoetide 2000-4000Part.
2. the hypertensive pharmaceutical composition of the treatment that contains frusemide as claimed in claim 1, is characterized in that, by as followsThe bulk drug composition of weight portion proportioning: frusemide 15-25 part, virgate lespedeza herb 2500-3500 part, buckwheat leaf 2500-3500 part, cucurbit2500-3500 part, asafoetide 2500-3500 part.
3. the hypertensive pharmaceutical composition of the treatment that contains frusemide as claimed in claim 2, is characterized in that, by as followsThe bulk drug composition of weight portion proportioning: 20 parts of frusemides, 3000 parts of virgate lespedeza herbs, 3000 parts of buckwheat leafs, 3000 parts, cucurbit, asafoetide3000 parts.
4. the hypertensive pharmaceutical composition of the treatment that contains frusemide as described in claim 1 or 2 or 3, is characterized in that, itsDosage form is granule.
5. the preparation method of the hypertensive pharmaceutical composition for the treatment of that contains frusemide described in claim 1 or 2 or 3, comprisesFollowing steps:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add 6 ~ 8 times of water gagings of injection volume for the 1st time, decoct 1 ~ 2Hour, add for the second time 4 ~ 6 times of water gagings of injection volume, decoct 0.5 ~ 1.5 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 55 ~ 65 DEG C ,-0.04 ~-0.08Mpa condition to relative density and is 1.08 ~ 1.12 clearCream, adds ethanol to being 75% containing alcohol amount, places 12 hours, filters, and it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, spraysMist is dry, obtains dry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material separately or mix with the acceptable auxiliary material of medicine, makes according to galenic pharmacy conventional method.
6. the preparation method of the hypertensive pharmaceutical composition for the treatment of that contains frusemide as claimed in claim 5, its feature existsIn,
In the step a of portion of institute, add 7 times of water gagings of injection volume for the 1st time, decoct 1.5 hours, add for the second time 5 times of amounts of injection volumeWater, decocts 1 hour; In described step b, thickening temperature be 60 DEG C, concentrated pressure is-0.06Mpa.
7. the preparation method of the hypertensive pharmaceutical composition for the treatment of that contains frusemide as claimed in claim 5, detailed stepAs follows:
A. by virgate lespedeza herb, buckwheat leaf, cucurbit, asafoetide boiling 2 times, add 7 times of water gagings of injection volume for the 1st time, decoct 1.5 littleTime, add for the second time 5 times of water gagings of injection volume, decoct 1 hour, merge decoction liquor, for subsequent use;
B. decoction liquor is condensed under 60 DEG C ,-0.06Mpa condition to relative density and is 1.08 ~ 1.12 clear cream, add ethanol extremelyBe 75% containing alcohol amount, place 12 hours, filter, it is 1.15 ~ 1.20 clear cream that filtrate is concentrated into relative density, and spraying is dried, and obtains dryDry medicinal powder;
C. frusemide and dry medicinal powder are mixed, granulate, obtain the active material of pharmaceutical composition of the present invention;
D. this active material separately or mix with the acceptable auxiliary material of medicine, makes according to galenic pharmacy conventional method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610175836.4A CN105596437A (en) | 2016-03-27 | 2016-03-27 | Pharmaceutical composition containing furosemide for treating hypertension and preparation method of pharmaceutical composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610175836.4A CN105596437A (en) | 2016-03-27 | 2016-03-27 | Pharmaceutical composition containing furosemide for treating hypertension and preparation method of pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105596437A true CN105596437A (en) | 2016-05-25 |
Family
ID=55977170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610175836.4A Withdrawn CN105596437A (en) | 2016-03-27 | 2016-03-27 | Pharmaceutical composition containing furosemide for treating hypertension and preparation method of pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105596437A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1958001A (en) * | 2005-11-01 | 2007-05-09 | 陈绮年 | Medication for treating high blood pressure |
-
2016
- 2016-03-27 CN CN201610175836.4A patent/CN105596437A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1958001A (en) * | 2005-11-01 | 2007-05-09 | 陈绮年 | Medication for treating high blood pressure |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
CN109758497B (en) | Traditional Chinese medicine composition and medicine for chronic heart failure and preparation method and application thereof | |
CN109908202A (en) | A kind of pharmaceutical composition and preparation method thereof for treating hyperuricemia | |
CN105596437A (en) | Pharmaceutical composition containing furosemide for treating hypertension and preparation method of pharmaceutical composition | |
CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
CN103877533B (en) | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof | |
CN109125699A (en) | Application of the Xiao Chaihu Tang in preparation treatment hepatic encephalopathy drug | |
CN115227757B (en) | Application of traditional Chinese medicine composition in preparation of antihypertensive drugs | |
CN115337348B (en) | Traditional Chinese medicine composition for treating heat-accumulation blood vessels | |
CN116036199B (en) | Application of traditional Chinese medicine composition in preparing medicine for assisting in treating chronic cough of children | |
CN115337347B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
CN106215080A (en) | A kind of pharmaceutical composition for the treatment of bronchial asthma of child containing Procaterol Hydrochloride and preparation method thereof | |
CN105687765A (en) | Lacidipine containing pharmaceutical composition for treating hypertension and preparation method thereof | |
CN105796952A (en) | Gliquidone-containing medicine combination for treating diabetes and preparation method thereof | |
CN105770205A (en) | Pharmaceutical composition containing felodipine and capable of treating hypertension and preparation method thereof | |
CN101491594A (en) | Soft-capsules for treating bronchitis and preparation method thereof | |
CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
CN105582327A (en) | Atenolol-containing medicine composition for treating high blood pressure and preparation method thereof | |
CN107669827A (en) | A kind of antihypertensive pharmaceutical composition and preparation method thereof | |
CN105770867A (en) | Tablets for treating tuberculous pericarditis and preparation method thereof | |
CN105012849A (en) | Traditional Chinese medicine composite for promoting perioperative period postoperative gastrointestinal function recovery and preparation method thereof | |
CN105582192A (en) | Hypertension-treating medicine composition containing bisoprolol fumarate and preparation method thereof | |
CN105582175A (en) | Labetalol-containing medicine composition for treating high blood pressure and preparation method thereof | |
CN105687874A (en) | Dihydrochlorothiazide (DCT) containing pharmaceutical composition for treating hypertension and preparation method thereof | |
CN105770220A (en) | Pharmaceutical composition containing losartan and capable of treating hypertension and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160525 |
|
WW01 | Invention patent application withdrawn after publication |